

**BEDFORDSHIRE, LUTON AND MILTON KEYNES AREA
PRESCRIBING COMMITTEE (APC)**

**Biologics for the Treatment of Ankylosing
Spondylitis and Non-radiographic Axial
Spondyloarthritis (nrAxial SpA) AFTER
failure of conventional treatment (in line
with NICE TAs)**

(Sept 2021)




Biologics for the Treatment of Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (nrAxial SpA) AFTER failure of conventional treatment (in line with NICE TAs), version 2, September 2021.

Previous version, March 2018, approved by the Bedfordshire and Luton Joint Prescribing Committee.

This algorithm is only applicable for use in patients with severe active disease (BASDAI and VAS ≥4) who have responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs.

Prescribing notes:

- Prescribe by brand name (due to availability of biosimilars*).
- Where possible, prescribe the least expensive agent (take into account individual patient factors e.g. presence of comorbidities, extra-articular manifestations).
- Infliximab* is recommended only if treatment is started with the least expensive infliximab product.
- When using BASDAI and spinal pain VAS scores, take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the responses to the questionnaires, and make any adjustments they consider appropriate.



TREATMENT REQUESTS BEYOND THE END OF THE ALGORITHM REQUIRE CONSIDERATION VIA THE IFR ROUTE